semaglutide deaths 2024 Contrary to popular belief: GLP-1 weight loss medications are NOT all about aesthetic weight loss, they REDUCE risk of cardiovascular death, all cause mortality, and now, progression of kidney disease! Just published The Effect of Semaglutide on
Description
Nominal Group Technique This study used the NGT method to gain insight into the adoption of the combined use of GLP1-RAs and SGLT2is in everyday clinical practice regarding the main topics of the scoping review: metabolic control, weight change, major cardiovascular events, hospitalizations for heart failure, major renal events, and adverse effects
Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, et al
These are often manageable, but their severity can vary considerably
Clinical trials show that gastrointestinal side effects, including constipation, occur in 2030% of semaglutide users
